HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 601–700 of 1,001
A sensitive and specific ELISA detects methionine sulfoxide-containing apolipoprotein A-I in HDL
Wang, X., Shao, B., Oda, M. N., Heinecke, J. W., Mahler, S. M., & Stocker, R. (2008) · Journal of Lipid Research · doi:10.1194/jlr.d800042-jlr200 · Cited by 23
HDL drug carriers for targeted therapy
Liu, X., Suo, R., Xiong, S.-L., Zhang, Q., & Yi, G. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.10.008 · Cited by 23
Varespladib methyl in cardiovascular disease
Rosenson, R. S., Fraser, H. I., Trias, J., & Hislop, C. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.517193 · Cited by 22
Querton, L., Buysschaert, M., & Hermans, M. P. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.002 · Cited by 26
Ishida, N., Iizuka, M., Kataoka, K., Okazaki, M., Shiraishi, K., Yagi, Y., Jobu, K., 横田, 淳., Oishi, M., Moriyama, H., et al. (2017) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2017.1386629 · Cited by 23
“Many epidemiological studies have shown that individuals with hypoalphalipoproteinaemia have a high risk of coronary artery disease (Robins et al. 2001; Hata et al. 2002; Barter et al. 2007; Yamashita 2016).”
BackgroundDerks, M. G. M., Anzures-Cabrera, J., Turnbull, L., & Phelan, M. (2012) · Clinical Drug Investigation · doi:10.1007/bf03256931 · Cited by 15
on behalf of the EVIDENT Group, Recio-Rodriguez, J. I., Gómez-Marcos, M. Á., Patino-Alonso, M. C., Puigdomènech, E., Notario‐Pacheco, B., Mendizabal-Gallastegui, N., de-la-Cal-dela-Fuente, A., Otegui-Ilarduya, L., Maderuelo-Fernández, J. Á., et al. (2015) · Nutrition Journal · doi:10.1186/s12937-015-0086-0 · Cited by 25
“Similarly, high-density lipoprotein (HDL) cholesterol concentrations are a strong inverse predictor of cardiovascular events [19] and elevated blood triglyceride (TG) concentrations and insulin resistance predict CVD and all-cause mortality in the general population [20, 21].”
Takayama, T., Komatsu, S., Ueda, Y., Fukushima, S., Hiro, T., Hirayama, A., & Saito, S. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.01.013 · Cited by 21
Lipid Measures and Cardiovascular Disease Prediction
van Wijk, D. F., Stroes, E. S. G., & Kastelein, J. J. P. (2009) · Disease Markers · doi:10.1155/2009/143680 · Cited by 24
Self-citationStatins in cardiometabolic disease: what makes pitavastatin different?
Ginsberg, H. N. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s1 · Cited by 29
Hypothyroidism, atherosclerosis and cardiovascular risk prevention
Duntas, L. H., & Feldt‐Rasmussen, U. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01202-z · Cited by 26
High-density lipoprotein cholesterol raising: does it matter?
Schofield, J. D., France, M. W., Ammori, B. J., Liu, Y., & Soran, H. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328362210d · Cited by 30
Simic, B., Mocharla, P., Crucet, M., Osto, E., Kratzer, A., Stivala, S., Kühnast, S., Speer, T., Doycheva, P., Princen, H. M. G., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.01.011 · Cited by 24
HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?
Rubenfire, M., & Brook, R. D. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0349-3 · Cited by 24
Biswas, T. K., Chakrabarti, S., Pandit, S., Jana, U., & Dey, S. K. (2014) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2014.09.002 · Cited by 26
Miyauchi, K., Daida, H., Morimoto, T., Hiro, T., Kimura, T., Nakagawa, Y., Yamagishi, M., Ozaki, Y., Kadota, K., Kimura, K., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0135 · Cited by 23
Norimatsu, K., Kuwano, T., Miura, S., Shimizu, T., Shiga, Y., Suematsu, Y., Miyase, Y., Adachi, S., Nakamura, A., Imaizumi, S., et al. (2016) · Heart and Vessels · doi:10.1007/s00380-016-0837-7 · Cited by 26
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East
Sayed, N., Waili, K. A., Alawadi, F., Al-Ghamdi, S. M. G., Almahmeed, W. A., Alnouri, F., Rukhaimi, M. A., Al‐Rasadi, K., Awan, Z. A., Farghaly, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.081 · Cited by 23
Self-citationHigh-density lipoprotein cholesterol concentration and acute kidney injury after noncardiac surgery
Zhou, Y., Yang, H., Zhang, H., & Zhu, X.-J. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01808-7 · Cited by 23
Risk Factors of Hypertension at UNRWA Primary Health Care Centers in Gaza Governorates
Abed, Y. A., & Abu-Haddaf, S. (2013) · ISRN Epidemiology · doi:10.5402/2013/720760 · Cited by 28
Lee, C., Tai, B., Lim, G.-H., Chan, M. Y., Low, A. F.-H., Tan, K. C. B., Chia, B. L., & Tan, H. C. (2010) · International journal of cardiac imaging · doi:10.1007/s10554-010-9777-y · Cited by 20
Heidarian, E., Kopaei, M. R., & Ashrafi, K. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 20
Dai, X., Zheng, Y., Tang, J., Yang, X.-M., Guo, Q., Zhang, J., Cheng, M., Song, F.-H., Liu, Z., Wang, K., et al. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1152-y · Cited by 18
“In contrast, high-density lipoprotein cholesterol (HDL-C) levels were inversely related to morbidity in patients with CAD [10].”
BackgroundEffect of 8-weeks intensive lifestyle intervention on LDL and HDL subfractions
Bajer, B., Rádiková, Ž., Havranová, A., Žitňanová, I., Vlček, M., Imrich, R., Sabaka, P., Bendžala, M., & Penesová, A. (2019) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2019.10.010 · Cited by 23
Wu, Y., Huang, W., Kor, C., Liu, K., Chen, T., Lin, P., & Wu, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248314 · Cited by 22
“High levels of HDL-C can lower your risk for cardiovascular diseases, while high LDL-C levels have opposite effects [36, 37].”
BackgroundXie, Z., Yao, M., Castro-Mejía, J. L., Ma, M., Zhu, Y., Fu, X., Huang, Q., & Zhang, B. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105447 · Cited by 19
Ogita, M., Miyauchi, K., Tsuboi, S., Shitara, J., Endo, H., Wada, H., Doi, S., Naito, R., Konishi, H., Dohi, T., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.06.036 · Cited by 21
Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
Hermans, M. P., & Fruchart, J. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311413952 · Cited by 20
Self-citationHamrefors, V., Orho‐Melander, M., Krauss, R. M., Hedblad, B., Almgren, P., Berglund, G. L., & Melander, O. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p001792 · Cited by 22
Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?
Rosenblit, P. D. (2012) · Current Cardiology Reports · doi:10.1007/s11886-011-0237-7 · Cited by 22
Ishigaki, Y., Kono, S., Katagiri, H., Oka, Y., OIKAWA, S.-I., & NTTP investigators (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.22095 · Cited by 22
Sun, H., Shen, J., Liu, T., Tan, Y., Tian, D., Luo, T., Lai, W., Dai, M., & Guo, Z. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.012 · Cited by 20
Köklü, E., Yüksel, İ. Ö., Arslan, Ş., Cagirci, G., Gençer, E. S., Koç, P., Çay, S., Kızılırmak, F., & Esin, M. (2015) · Angiology · doi:10.1177/0003319715613916 · Cited by 20
Asghari, S., Aref‐Eshghi, E., Godwin, M. S., Duke, P. S., Williamson, T. S., & Mahdavian, M. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007954 · Cited by 21
Lebdai, S., Mathiéu, R., Léger, J., Haillot, O., Vincendeau, S., Rioux-Leclercq, N. C., Fournier, G., Perrouin‐Verbe, M., Doucet, L., Azzouzi, A.-R., et al. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.09.026 · Cited by 21
Horiuchi, Y., Ohkawa, R., Lai, S.-J., Shimano, S., Hagihara, M., Tohda, S., Kameda, T., & Tozuka, M. (2019) · Bioscience Reports · doi:10.1042/bsr20190213 · Cited by 21
Ouyang, J., Hou, Q., Wang, M., Zhao, W., Feng, D., Pi, Y., & Sun, X. (2020) · Canadian Journal of Animal Science · doi:10.1139/cjas-2019-0119 · Cited by 21
“Accordingly, increased HDL content could inhibit the levels of CHOL which has been shown to induce cardiovascular diseases (Barter et al. 2007).”
BackgroundZhang, Y., Li, J., Liu, C., Yu, H., Chen, C., Bi, C., Fang, C., Ma, H., Li, A., Dong, Q., et al. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s295252 · Cited by 23
High prevalence of cardiovascular disease in South Asians: Central role for brown adipose tissue?
Boon, M. R., Bakker, L. E. H., van der Linden, R. A. D., van Ouwerkerk, A. F., de Goeje, P. L., Counotte, J., Jazet, I. M., & Rensen, P. C. N. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.1003634 · Cited by 23
Niacin's role in the statin era
Brooks, E. L., Kuvin, J. T., & Karas, R. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.498818 · Cited by 22
Hu, G., Cui, Y. A., Jousilahti, P., Sundvall, J., Girman, C. J., Antikaínen, R., Laatikainen, T. K., & Tuomilehto, J. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711428242 · Cited by 20
Zhao, S., Wang, F., Dai, Y., Lin, L., Tong, Q., Liao, Y., Yin, Y., Wang, G., Yan, Y., Li, X., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.234 · Cited by 22
Genest, J. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.033 · Cited by 20
Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries
Nicholls, S. J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832ec396 · Cited by 19
Prediction and Risk Stratification of Cardiovascular Disease in Diabetic Kidney Disease Patients
Ren, J., Liu, D., Li, G., Duan, J., Dong, J., & Liu, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.923549 · Cited by 22
“Through reverse cholesterol transport (RCT), HDL can protect against plaque formation and development in the prevention of CVD (54).”
BackgroundMariadoss, S., & Augustin, F. (2023) · Journal of King Saud University - Computer and Information Sciences · doi:10.1016/j.jksuci.2023.101659 · Cited by 26
“M3: Total cholesterol (TC) (Barter et al., 2007) High cholesterol levels during pregnancy may also increase the risk of preeclampsia, a potentially severe complication characterized by hypertension and damage to other organs.”
Khera, A. V., & Rader, D. J. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.12.003 · Cited by 19
Guo, T., Yin, R., Wu, J., Lin, Q.-Z., Shi, G.-Y., Shen, S.-W., SUN, J.-Q., Li, H., Lin, W., & YANG, D.-Z. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3825 · Cited by 19
Duffy, D., Holmes, D. N., Roe, M. T., & Peterson, E. D. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.01.029 · Cited by 22
Bartolo, B. A. D., Scherer, D. J., & Nicholls, S. J. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.62906 · Cited by 20
Al-Dashti, Y. A., Holt, R. R., Carson, J. G., Keen, C. L., & Hackman, R. M. (2019) · Journal of Medicinal Food · doi:10.1089/jmf.2018.0209 · Cited by 20
Effect of Flaxseed Powder on Cardiovascular Risk Factor in Dyslipidemic and Hypertensive Patients
Haghighatsiar, N., Askari, G., Saraf‐Bank, S., Feizi, A., & Keshmiri, H. (2019) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_563_17 · Cited by 25
“One study showed that 30% CVD incidence will be decreased by 10% reduction in serum concentrations of total cholesterol (TC).[12] Lucas et al.”
Izuhara, M., Ono, K., Shiomi, H., Morimoto, T., Furukawa, Y., Nakagawa, Y., Shizuta, S., Tada, T., Tazaki, J., Horie, T., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.010 · Cited by 22
Rouvre, M., Vol, S., Gusto, G., Born, C., Lantieri, O., Tichet, J., & Lecomte, P. (2010) · Annals of Epidemiology · doi:10.1016/j.annepidem.2010.07.097 · Cited by 23
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: A simulation study
Folse, H. J., Goswami, D., Rengarajan, B., Budoff, M. J., & Kahn, R. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.027 · Cited by 20
Ling, Y., Jiang, J., Wu, B., & Gao, X. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.017 · Cited by 21
Horiuchi, Y., Ohkawa, R., Lai, S.-J., Yamazaki, A., Ikoma, H., Yano, K., Kameda, T., & Tozuka, M. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0284 · Cited by 19
MicroRNA-Management of Lipoprotein Homeostasis
Sun, X., & Feinberg, M. W. (2014) · Circulation Research · doi:10.1161/circresaha.114.304228 · Cited by 19
Peréz‐Beltrán, Y. E., González‐Becerra, K., Rivera‐Íñiguez, I., Martínez‐López, E., Ramos-López, O., Alcaraz-Mejia, M. I., Rodriguez‐Echevarría, R., Sáyago‐Ayerdi, S. G., & Mendivil, E. J. (2023) · Nutrients · doi:10.3390/nu15204324 · Cited by 20
“Interestingly, it has been shown in models adjusted for covariates that an increase of 1 mg/dL in the HDL-c level reduces the risk of major cardiovascular events by 1.1% [43].”
BackgroundInfluentialLipoproteins and Cardiovascular Diseases
Saba, A. B., & Oridup, O. (2012) · InTech eBooks · doi:10.5772/48132 · Cited by 19
Emerging drugs for hyperlipidemia
Paras, C., Hussain, M. M., & Rosenson, R. S. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.481282 · Cited by 20
Reyes‐Soffer, G., Rondon-Clavo, C., & Ginsberg, H. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.563506 · Cited by 19
The role of cholesterol and statins in stroke
Navi, B. B., & Segal, A. Z. (2008) · Current Cardiology Reports · doi:10.1007/s11886-009-0002-3 · Cited by 18
“In the TNT study, HDL-C was independently associated with major cardiovascular events, including fatal or nonfatal stroke, even after LDL-C had been taken into account [ 22 ].”
MethodPrevalence and Risk Distribution of Residual Dyslipidemia in Statin-Treated Patients in Greece
Liberopoulos, E. N., Vlasserou, F., Mitrogianni, Z. O. I., Papageorgantas, I., & Elisaf, M. (2011) · Angiology · doi:10.1177/0003319711410226 · Cited by 18
Farp2 and Stk25 Are Candidate Genes for the HDL Cholesterol Locus on Mouse Chromosome 1
Su, Z., Cox, A., Shen, Y., Stylianou, I. M., & Paigen, B. J. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.178384 · Cited by 20
Prenatal hypoxia promotes atherosclerosis via vascular inflammation in the offspring rats
Zhang, P., Zhu, D., Chen, X., Li, Y., Li, N., Gao, Q., Li, L., Zhou, X., Lv, J., Sun, M., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.028 · Cited by 20
Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL
Shah, P. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833f0382 · Cited by 16
Honda, S., Sidharta, S. L., Shishikura, D., Takata, K., Giovanni, G. D., Nguyen, T., Janssan, A., Kim, S. W., Andrews, J., Psaltis, P. J., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.016 · Cited by 19
Sun, L., Xu, G., Lv, M., Zhou, H., Huang, H.-F., & Luo, Q. (2018) · Journal of Women s Health · doi:10.1089/jwh.2017.6793 · Cited by 19
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
Nakazawa, M., Arashi, H., Yamaguchi, J., Ogawa, H., & Hagiwara, N. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.005 · Cited by 18
Kim, S. H., & Son, K. Y. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-020-01426-0 · Cited by 19
Barn, K., Laftavi, M. R., Pierce, D., Ying, C., Boden, W. E., & PANKEWYCZ, O. G. (2009) · Transplant International · doi:10.1111/j.1432-2277.2009.01021.x · Cited by 18
Tsai, M. Y., Li, N., Sharrett, A. R., Shea, S., Jacobs, D. R., Tracy, R. P., Arnett, D. K., Arends, V. L., & Post, W. S. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.107995 · Cited by 21
Adaramoye, O. A., & Akanni, O. O. (2014) · Advances in Pharmacological Sciences · doi:10.1155/2014/605425 · Cited by 25
Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases
Τζιόμαλος, Κ., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010085 · Cited by 22
Pirim, D., Wang, X., Niemsiri, V., Radwan, Z. H., Bunker, C. H., Hokanson, J. E., Hamman, R. F., Barmada, M. M., Demirci, F. Y., & Kamboh, M. I. (2015) · Metabolism · doi:10.1016/j.metabol.2015.09.020 · Cited by 20
Cerda, Á., Hirata, M. H., & Hirata, R. D. C. (2012) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2012-0007 · Cited by 20
“Evidences have provided a strong relationship between statin-induced LDL cholesterol reduction and low risk for acute myocardial infarction and stroke; however, some patients that achieve a low LDL cholesterol level remain at cardiovascular risk (94) .”
Liu, X., Ren, K., Suo, R., Xiong, S.-L., Zhang, Q., Mo, Z., Tang, Z., Jiang, Y., Peng, X., & Yi, G. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-016-0504-6 · Cited by 20
Park, J. H., Mun, S., Choi, D. P., Lee, J. Y., & Kim, H. C. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0548-6 · Cited by 20
‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia
Jacobson, T. A. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02547.x · Cited by 18
Environmental Factors Modifying HDL Functionality
Kostara, C. E., Kosmas, C. E., Sourlas, A., & Guzman, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210714155422 · Cited by 18
Li, L., Zhong, S., Li, R., Liang, N., Zhang, L., Shen, X., Xu, X., Chen, X., Chen, S., Tao, Y., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155869 · Cited by 20
Increased BMI and Blood Lipids Are Associated With a Hypercoagulable State in the Moli-sani Cohort
Kremers, R., Castelnuovo, A. F. D., van der Vorm, L. N., Costanzo, S., Ninivaggi, M., Cerletti, C., Huskens, D., Curtis, A. D., Gialluisi, A., Bai, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.897733 · Cited by 19
“This is in accordance with the known effects of LDL-C and HDL-C on the risk of CVD: LDL-C is considered to be a risk factor for atherothrombosis, whereas HDL-C is reported to be protective (57), although there is controversy whether the latter applies to certain patient subgroups (58).”
ResultPhysical Activity in the Management of Patients with Coronary Artery Disease: A Review
Backshall, J., Ford, G. A., Bawamia, B., Quinn, L., Trenell, M. I., & Kunadian, V. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000032 · Cited by 22
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 38
High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities
Santos‐Gallego, C. G., & Badimón, J. J. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.10.023 · Cited by 19
Cea‐Calvo, L., Lozano, J. V., Fernández, C., Llisterri, J. L., Martí-Canales, J. C., Aznar, J., Gil-Guillén, V. F., Redón, J., & on behalf of the investigators of the PREV-ICTUS study (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01902.x · Cited by 20
Mixed dyslipidemias in primary care patients in France
Ambegaonkar, B. M., LaForest, Souchet, Sazonov, & Ganse, E. H. V. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s27668 · Cited by 18
“However, low serum levels of high-density lipoprotein cholesterol (HDL-C) and elevated levels of triglycerides also increase the risk of CHD, even in patients treated with statins and with low LDL-C levels.(9) Serum levels of HDL-C and triglycerides tend to be inversely correlated, likely reflecting their respective p…”
Hourcade‐Potelleret, F., Laporte, S., Lehnert, V., Delmar, P., Benghozi, R., Torriani, U., Koch, R., & Mismetti, P. (2015) · Heart · doi:10.1136/heartjnl-2014-306691 · Cited by 18
ELISA System for Human Endothelial Lipase
Ishida, T., Miyashita, K., Shimizu, M., Kinoshita, N., Mori, K., Sun, L., Yasuda, T., Imamura, S., Nakajima, K., Stanhope, K. L., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.187914 · Cited by 17
Derks, M., Kawamura, H., Abt, M., Meneses‐Lorente, G., Phelan, M., & Ishikawa, T. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.05.046 · Cited by 17
Narayanan, R. P., Fu, B., Oliver, R. L., Siddals, K. W., Donn, R. P., Hudson, J. E., White, A. E., Laing, I., Ollier, W., Heald, A. H., et al. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213499145 · Cited by 17
Zhao, L., Xu, T., Li, Y., Luan, Y., Lv, Q., Fu, G., & Zhang, W. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01304-9 · Cited by 17
Dishy, V., Liu, F., Ebel, D. L., Atiee, G. J., Royalty, J. E., Reilley, S. F., Paolini, J. F., Wagner, J. A., & Lai, E. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009332246 · Cited by 17
Dullaart, R. P. F., Perton, F. G., Kappelle, P. J. W. H., de Vries, R., Sluiter, W. J., & van Tol, A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.09.019 · Cited by 20
Relationship between Serum Lipid Values and Atherosclerotic Burden in the Proximal Thoracic Aorta
Kohsaka, S., Jin, Z., Rundek, T., Homma, S., Sacco, R. L., & Tullio, M. R. D. (2010) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00437.x · Cited by 17
Fukami, K., Yamagishi, S., Sakai, K., Nasu, M., & Okuda, S. (2014) · Clinical Kidney Journal · doi:10.1093/ckj/sfu082 · Cited by 17
Gao, S., Wang, C., Li, W., Shu, S., Zhou, J., Yuan, Z., & Wang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.09.085 · Cited by 17
Murray, A., Cluett, C., Bandinelli, S., Corsi, A. M., Ferrucci, L., Guralnik, J. M., Singleton, A., Frayling, T. M., & Melzer, D. R. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp161 · Cited by 19
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.